Introduction: In 2016, the orally administered fixed-dose combination of dexketoprofen 25 mg and tramadol 75 mg (DKP/TRAM FDC) was approved in Europe for short-term treatment of moderate-to-severe acute pain, an indication that encompasses a wide range of post-operative and non-surgical painful condi-tions. This has suggested the necessity to have a clearer indication on its clinical use, with the support of expert pain clinicians, working in different medical specialities, and reinforced by the data present in the literature. Methods: With the aim of assisting clinicians in the use of DKP/TRAM FDC in daily practice, two rounds of a modified Delphi process were conducted. In the first round, a board of nine experts developed a series of consensus statements based on available evidence, and their clinical experience, with DKP/TRAM FDC. In the second round, 75 clinicians with extensive experience in pain management expressed individually their agreement with the statements, using a dedicated online platform. Consensus was defined as at least 70% agreement. Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.9810575.
INTRODUCTION
This decade has witnessed important advances in understanding the pathophysiologic basis of pain. The increasing implementation of standardized pain evaluation, treatment protocols and the routine use of multimodal analgesic techniques are hopeful signs that improvements in pain management are likely to continue in the years ahead [1] . Combining analgesics that act by different mechanisms of action potentially provides multimodal coverage in a broad spectrum of painful conditions and enables individual agents to act with potentially additive or synergistic effects [2] . A rational multimodal approach can also reduce the frequency of adverse effects for a better efficacy-to-safety ratio [3] . Orally administered fixed-dose analgesic combinations possibly offer additional advantages over extemporaneous combinations, including ease of administration, reduction of pill burden and potential for greater patient adherence [4] .
The orally administered fixed-dose combination of dexketoprofen 25 mg and tramadol 75 mg (DKP/TRAM FDC) has shown an analgesic efficacy greater than that achieved by either component in monotherapy in the wellestablished human pain models of dental pain [5, 6] , soft tissue surgery [7] and joint replacement surgery [8] . The complementary mechanisms of action that contribute to DKP/TRAM FDC multimodal analgesia include (a) analgesic and anti-inflammatory action of dexketoprofen (and its central action); (b) opioid receptor activation by tramadol; (c) indirect activation of central descending monoaminergic pathways by tramadol, with consequent inhibition of nociceptive transmission to the brain [9] .
In 2016, DKP/TRAM FDC was approved for use in Europe by a decentralized procedure. This same formulation is under registration in many countries outside of Europe. DKP/TRAM FDC is indicated for short-term symptomatic treatment of moderate-to-severe acute pain that includes a wide range of post-operative and non-surgical painful conditions. As significant advances in the use of a medication tend to occur well after drug approval, ongoing and future long-term studies of DKP/ TRAM FDC are expected to yield important information about painful conditions that will benefit most from treatment with this new analgesic combination. However, until such data are available, a modified Delphi study appears a particularly well-suited method to develop consensus statements which reflect the collective prescribing and management patterns of experts with considerable knowledge and experience in the management of perioperative and non-surgical pain.
With the purpose of improving pain management, a panel of experts evaluated selected statements, with the Delphi method, with regard to the utilization of DKP/TRAM FDC.
METHODS

Design and Identification of Experts
The Delphi method [10] is an indirect, anonymous, iterative process aimed at achieving consensus among experts in complex scenarios where knowledge of a particular topic is available, but definitive experiments to prove the points are lacking [11] . It is a widely adopted methodology in health research in the fields of policy analysis, technology assessment, and education and training; it is also used for developing consensus statements on disease management and drug therapy [12] .
A modified Delphi method [13] was used to generate and achieve consensus on the use of DKP/TRAM FDC in clinical practice. The definition of consensus was determined before the analysis, and it was set at at least 70% agreement [14] . Investigators were blinded to the results during analysis. The process began identifying a board of international experts with at least 15 years' experience in pain management and at least one peer-reviewed publication on analgesic combinations within the last 5 years. Nine identified experts, authors of this article, agreed to participate in the study. Between March 2017 and November 2017, two Delphi rounds were conducted. Descriptive statistical analyses were performed using SPSS ver. 23 (IBM Corp., Armonk, NY, USA).
Delphi Rounds
On the basis of available evidence about DKP/ TRAM FDC, the board of nine international experts supported the research team members in defining the main items of an open-ended questionnaire. In fact, using a dedicated online platform, the experts were asked to respond individually to open-ended questions. On the basis of the answers, 31 consensus statements were developed. Subsequently, the identified international experts met in person in June 2017. During the meeting, the members of the board commented individually on the consensus statements, indicating which of them were to be discarded. The experts were also invited to include comments and any literature data that they considered useful to propose additional statements. Plenary discussion on the revised list of statements was held. Following the meeting, a final list of 28 topically organized consensus statements was distributed by email to the board of experts for final approval. At this stage, the board members proposed only minor linguistic modifications.
In the second Delphi round, research team members defined, with the assistance of the board, a list of 118 experts in pain management (the panellists) working in centres of excellence located in clinical centres or university departments. Only clinicians with extensive experience in pain management were invited by email to participate in the Delphi process. Using a dedicated online platform, clinicians were invited to indicate their level of 'agreement' by rating each statement on a 5-point Likert-type scale (1-'strongly disagree', 2-'disagree', 3-'partially agree', 4-'agree', 5-'strongly agree'). A reminder was sent to participants who had not yet responded by the given deadline. Participants' characteristics, such as gender, medical specialty, years of experience in pain management and the employment continent, were collected. The Delphi platform has been kept online for 10 weeks. No face-to-face meetings were held among panellists in order to maintain anonymity and to cast a wide geographical net. Anonymised results from round 2 circulated among the board of experts during a second face-to-face meeting. Statements for which at least 70% consensus was not achieved were reviewed and openly discussed by the experts. Plenary discussion on consensus statements was held.
The authors declare that, according to Italian law, the approval of an ethics committee is not required. The authors declare that the study is conducted in accordance with the Helsinki Declaration. The authors also declare under their own responsibility that the panel members gave their consent to participate in the study and have given consent to publish the data presented in the submitted manuscript, in an anonymous way.
RESULTS
In Delphi round 1, 28 consensus statements were defined with the assistance of the board of nine international experts in pain management. The statements were grouped into four categories: (1) pharmacological features of DKP/ TRAM, (2) clinical use of DKP/TRAM in postoperative pain management, (3) clinical use of DKP/TRAM in non-surgical pain and (4) advantages of DKP/TRAM.
In round 2, the identified consensus statements were introduced using an online questionnaire. A panel of 75 experts responded to the e-Delphi questionnaire (response rate 63.6%). As shown in Table 1 , 58 responders were men and 17 women; 57 responders were based in Europe and 18 in other continents. The majority of participants were anaesthesiologists (n = 48). Almost 90% of panellists (n = 67) declared more than 10 years' experience in pain management.
In total, 19 of the 28 statements reached the defined level of consensus, as at least 70% of participants had indicated a score of 4 (agree) or 5 (strongly agree). The complete list of statements to reach consensus is provided in Table 2 . Nine statements failed to reach the minimum level of agreement and were neither accepted nor re-evaluated ( Table 3 ). Percentages of agreement for each statement are reported in the online only supplementary materials (Tables S1 and S2).
DISCUSSION
The purpose of this Delphi study was to develop practical guidance for clinicians about the use of DKP/TRAM FDC in routine clinical practice. We used a modified Delphi method to build consensus among a panel of experts with substantial experience in pain management. The major modification to the standard Delphi technique involved originating the process with a set of pre-formulated statements developed by a group of international experts with in-depth knowledge about the use of analgesic combinations and particularly about DKP/TRAM FDC.
In this section, we present final consensus statements ( Table 2 ) and deadlocked statements (Table 3) , with supplementary comments, which reflect the reasoning behind them, based on experts' discussion, and supported by references as needed.
Pharmacological Features of DKP/TRAM
DKP/TRAM FDC combines two well-known
drugs with proven efficacy and safety profile. 2. In moderate-to-severe acute pain, the FDC of DKP (a rapidly acting NSAID) plus TRAM (a long-lasting opioid) provides effective analgesia due to its multiple modes and sites of action. 3. In moderate-to-severe acute nociceptive somatic or visceral pain, the complementary pharmacokinetic profile of DKP with TRAM provides effective analgesia with rapid onset and long duration.
Supplementary Comment: DKP/TRAM FDC provides multimodal analgesia via different mechanisms of action in the peripheral and central nervous systems [9] . In DKP/TRAM FDC, the rapid onset of analgesic effect of dexketoprofen [15] is accompanied and complemented by the prolonged duration of action of tramadol TRAM FDC is likely to be envisaged for minor orthopaedic surgeries such as rotator cuff repair, arthroscopic shoulder and knee surgeries, bunionectomy (hallux valgus surgery), meniscectomy, debridement of the median nerve and fracture management. 6. DKP/TRAM FDC is likely to be an effective analgesic in minor surgeries such as appendectomies, endoscopic bladder surgery, endoscopic prostatectomy (TURP), plastic surgery of soft parts, rhino-plastic, endoscopic video thoracic surgery, hernia repair, laparoscopic cholecystectomy, ocular surgery, skin surgery, abscess drainage. 7. DKP/TRAM FDC has provided effective and rapid post-operative pain relief in surgical removal of impacted wisdom teeth and dental surgeries.
Supplementary Comment: In well-designed, randomized clinical trials [5, 8] , DKP/TRAM Advantages of the DKP/TRAM FDC XVI DKP/TRAM FDC offers additional advantages over non-fixed combinations, including ease of administration, reduction of pill burden and will improve adherence by patients XVII The oral route of administration of DKP/TRAM FDC improves patient compliance and adherence to treatment and will be of advantage in the outpatient setting XVIII DKP/TRAM FDC could be of great value when other single or combined drugs were less efficacious or could not be tolerated because of adverse side effects XIX In moderate-to-severe acute pain, the DKP/TRAM FDC generates effective and rapid analgesia reducing burden of pain. This in turn may potentially have a positive impact on psychosocial aspects of acute pain such as psychological vulnerability, stress, higher healthcare utilization and reduced labour force participation FDC was effective in moderate-to-severe postoperative acute pain management. It was also superior to the combination paracetamol/tramadol (650/75 mg) [6] .
In major surgeries such as hip replacement, DKP/TRAM FDC showed superior and sustained efficacy for post-operative pain control compared with individual components at the same (i.e. dexketoprofen 25 mg) or higher (i.e. tramadol 100 mg) doses. This, in turn, facilitates early patient mobilization, lowering thromboembolic risk, shortening hospitalization and timely starting of rehabilitation [17] .
DKP/TRAM FDC can also be envisaged for use in a wide range of minor or day case surgeries. As an increasing number and complex elective operations are being performed on an ambulatory (or short-stay) basis, effective multimodal analgesic regimens that can be managed successfully at home by patients and their caregivers are required [1] .
Clinical Use of DKP/TRAM in Non-Surgical Pain
DKP/TRAM FDC is likely to provide a good
means for effective pain management in moderate-to-severe acute dental pain due to its shorter time to onset of analgesia and its anti-inflammatory activity. 2. Owing to its pharmacological profile, DKP/ TRAM FDC could be an important tool in Table 3 Statements which failed to achieve at least 70% consensus Supplementary Comment: Recent systematic reviews [18] and clinical recommendations [19] focus primarily on post-operative acute pain although non-surgical acute pain (e.g. posttrauma pain or acute flares of osteoarticular pain) should also be addressed. DKP/TRAM FDC provided effective post-operative pain control after third mandibular molar tooth extraction [5] , which is a model of acute pain frequently used to investigate the pharmacodynamics properties of analgesic molecules (i.e. onset/ offset, dose-response and potency) [20] . Efficacy in dental model is highly predictive of efficacy in later stage models [21] . Furthermore, third molar surgery is a common procedure with sufficient patient numbers to make these studies relatively easy to perform [22] . In patients with moderate-to-severe acute dental pain, the analgesic and anti-inflammatory activity of orally administered dexketoprofen trometamol was found to be similar to that of ibuprofen, with a shorter time to onset of analgesia [23] . On these bases, DKP/TRAM FDC is envisaged for use to relieve moderate-to-severe non-surgical acute dental pain. DKP/TRAM FDC also represents an interesting option for acute exacerbations of osteoarticular pain owing to its pharmacological profile and multimodal approach [9] . Of note, osteoarticular pain includes nociceptive and neuropathic mechanisms that are involved in both the local and central levels and may present with different clinical features: constant and intermittent pain, with or without a neuropathic component, and with or without central sensitization [24, 25] . By targeting different sites of action, DKP/TRAM FDC is particularly suitable for osteoarticular pain that arises from different body structures such as joints and muscles [9] .
Advantages of DKP/TRAM
DKP/TRAM FDC offers additional advan-
tages over non-fixed combinations, including ease of administration, reduction of pill burden and will improve adherence by patients. 2. The oral route of administration of DKP/ TRAM FDC improves patient compliance and adherence to treatment and will be of advantage in the outpatient setting.
DKP/TRAM FDC could be of great value
when other single or combined drugs were less efficacious or could not be tolerated because of adverse side effects. 4. In moderate-to-severe acute pain, the DKP/ TRAM FDC generates effective and rapid analgesia reducing burden of pain. This in turn may potentially have a positive impact on psychosocial aspects of acute pain such as psychological vulnerability, stress, higher healthcare utilization and reduced labour force participation.
Supplementary Comment:
We strongly advocate for the use of fixed-dose analgesic combinations such as DKP/TRAM FDC in the management of moderate-to-severe acute pain. In particular, orally administered fixed-dose analgesic combinations may improve patient adherence to treatments [4] .
In recent years, the work-, social-, and family-related consequences of poorly managed pain have been extensively investigated [26, 27] . In related fashion, the implications of inadequate acute pain management may affect negatively on individual stress, healthcare resource utilization and labour force participation [27] . All this implies that acute moderateto-severe pain must be treated as soon and as efficaciously possible.
Statements for Which at Least 70% Consensus Was Not Achieved (a) DKP/TRAM FDC provides a good means for effective analgesia at reduced doses of individual agents with a potential reduction of opioid dose-related adverse events such as constipation, respiratory depression, nausea and vomiting. (b) Safety profile of DKP/TRAM FDC is fully in line with that previously known for the single agents in monotherapy. (c) DKP/TRAM FDC has a potential advantage in moderate-to-severe acute post-operative pain owing to its rapid onset of action. This in turn may reduce risks of medical complications and of developing chronic pain, allowing a fast hospital discharge and a more effective outpatient pain management. (d) DKP/TRAM FDC will provide effective analgesia in major surgeries, when the oral route (or the switch to it) is feasible. (e) The orally administered DKP/TRAM FDC provides effective analgesia in moderateto-severe acute symptomatic painful conditions and its use is likely to be shown as beneficial in a wide range of non-surgical clinical conditions. (f) In acute cervical pain, DKP/TRAM FDC through very effective analgesia may allow one to reduce the muscular tension and the consequent spasmodic pain. (g) DKP/TRAM FDC has the potential to be useful for renal colic pain and dysmenorrhoea, a distressing condition with important visceral component and particularly for secondary dysmenorrhoea caused by endometriosis, since the two components (DKP and TRAM) have proven efficacy in those pain syndromes.
(h) In specific pain models, less rescue medications were needed when the DKP/TRAM FDC was used. (i) Compared to the single agents in monotherapy, DKP/TRAM FDC offers potential benefits such as longer time to re-medication and better patient global evaluation.
Supplementary Comment: The main premise of opioid-containing analgesic combinations is to decrease the consumption of opioids, and hence reduce the frequency of opioid-related adverse events [19] . More research is needed to evaluate if the use of the DKP/TRAM FDC is associated with a reduction of opioid dose-related adverse events.
The percentage of agreement for statement (c) fell slightly below the predefined level of agreement. Of note, recent studies [28] [29] [30] [31] [32] indicate that poorly managed post-operative pain can result in chronic pain. Furthermore, according to results of a cross-sectional survey on a sample of 1030 patients [33] , post-operative chronic pain affects 38% of patients undergoing total hip arthroplasty. More research on the role of DKP/TRAM FDC in preventing the development of chronic pain is needed.
Likewise, statement (d) did not reach consensus. In this regard, the 2016 guideline from the American Pain Society and the American Society of Regional Anesthesia and Pain Medicine for management of post-operative pain [19] strongly recommends oral over intravenous administration of opioids for post-operative analgesia in patients able to use the oral route.
Despite the availability of scientific literature, statement (h) did not reach the predefined level of agreement. In pivotal studies of DKP/ TRAM FDC [5, 7] , patients who received the analgesic combination experienced longer time to first use of rescue medication in comparison with single agents DKP 25 mg and TRAM 100 mg. This suggests that findings from clinical trials diffuse slowly into clinical practice, highlighting the need to bridge the gap between research and practice.
Strengths and Limitations of the Study
Our study has several strengths. Rather than begin the Delphi procedure with an open question and invite suggestions from panellists, the list of consensus statements they voted on was derived from the existing clinical literature and formulated by a board of international experts with strong expertise in pain management, and especially in the use of analgesic combinations, including DKP/TRAM FDC. During the first face-to-face meeting, experts could explain and defend their own ideas, potentially improving the quality of the initial draft of consensus statements. The sample size of panellists was relatively large compared with other Delphi studies, and electronic data collection allowed high clinician participation with a wider geographical net.
The study also had some limitations. The potential sample of panellists was large and comprised experienced people from different geographical areas; some panellists were based in countries where DKP/TRAM FDC was not released yet or not in widespread use.
For expected adverse events related to the drug, please refer to the summary of product characteristics of DKP/TRAM FDC [34] .
CONCLUSIONS
DKP/TRAM FDC is a rapidly acting, long-lasting, multimodal analgesic combination that is effective and generally well tolerated in patients with moderate-to-severe acute pain [9] .
Additional long-term clinical studies are expected to identify acute painful conditions that will benefit most from treatment with DKP/ TRAM FDC. Meanwhile, the consensus statements may help clinicians applying the results of clinical studies and clinical recommendations to routine-care settings, thus providing guidance for use of this new analgesic combination in moderate-to-severe post-operative and non-surgical acute pain.
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